Abstract: The present invention provides a therapeutic agent and methods thereof for the treatment for irritable bowel syndrome. The agent comprises a compound represented by formula (I): wherein, R1 represents an optionally substituted hydrocarbon group, etc., R2 represents a hydrogen atom or an optionally substituted hydrocarbon group, R3 represents a hydrogen atom, an optionally substituted hydrocarbon group, etc., X represents CHR4, NR4, CO, O or S (wherein, R4 represents a hydrogen atom, an optionally substituted hydrocarbon group, etc.), Y represents C, CH or N, represents a single bond or double bond, ring A represents an optionally substituted 5- to 7-membered oxygen-containing heterocyclic ring, ring B represents an optionally substituted benzene ring, and m represents an integer of 1 to 4, or a salt thereof, wherein the compound represented by formula (I) or a salt thereof is (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.

Abstract: An external preparation containing acetylsalicylic acid or its pharmaceutically acceptable salt as an active ingredient for treating anal diseases having therapeutic activity on hemorrhoids (internal hemorrhoid, external hemorrhoid), hemorrhoidal disease owing to anal fissure and other anal diseases together with activity on pain and pruritus.

Abstract: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease.

Abstract: Method for therapeutic treatment of inflammatory bowel disease, including Crohn's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a retinoid as an active ingredient to treat the inflammatory bowel disease, the retinoid being selected from the group consisting of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid, 4-[(3,5-bis-trimethylsilylphenyl)carboxamido]benzoic acid, 4-[2,3-(2,5-dimethyl-2,5-hexano)dibenzo[b,f][1,4]thiazepin-11-yl]benzoic acid, and 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid.

Abstract: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-?. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-? production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Abstract: Compounds selectively inhibiting neuronal nitric oxide synthase (nNos), such compounds of a formula wherein the variables are defined, herein.

Abstract: The present invention relates to amino-salicylic-aminophenyl compounds for use in the treatment of the inflammatory component of celiac disease. These compounds act by blocking the cytokines released in celiac disease and are specifically useful in the treatment of refractory cases.

Abstract: A method for preparing compositions, comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and ?-linoleic acid (ALA), that are administered to felines for treating feline inflammatory bowel disease (IBD).

Abstract: The present invention provides the invention provides methods of reducing phosphate nephropathy in a mammal suffering from impairment of renal function, including administering to the mammal an amount of citrate that is effective to reduce serum phosphorous concentration.

Abstract: Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels in subjects in need thereof are disclosed herein. The methods can be useful for subjects having age related decline in testosterone, exercise induced decline in testosterone, and/or hypogonadism.

Abstract: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such inhibitors are contemplated by the present invention.

Abstract: The present invention encompasses methods for treating neurofibromatosis.

Abstract: The present invention relates to dosage forms for oral administration of therapeutic formulations, adapted to provide immediate and/or sustained-release of therapeutic substances, particularly for oral administration of vitamins. There is provided a dosage form for oral administration of a vitamin, comprising: a liquid phase containing a vitamin, e.g. Vitamin C in a relatively fast release form and a solid phase suspended in the liquid phase and containing a vitamin e.g. Vitamin C in a relatively slow release form.

Abstract: The invention features low-dosage rifalazil compositions which are useful for the treatment of bacterial infections.

Abstract: The present invention relates to methods for treating bowel disorders using calcimimetics.

Abstract: Disclosed is the use of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid or its pharmaceutically acceptable salt for the reduction of hair loss; for hair regrowth, hair toning and hair growth; and for the treatment of female hirsutism.

Abstract: The subject invention provides methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising topiramate. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury.

Abstract: The present invention provides compositions and methods for treating inflammatory bowel disease. In particular, the present invention provides methods of therapeutically treating symptoms of inflammatory bowel disease using compositions comprising an angiotensin converting enzyme (ACE) inhibitor and polyethylene glycol.

Abstract: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.

Abstract: A treatment to differentially regulate the expression of genes related to irritable bowel syndrome is provided.